Publication Balykova L, Infektsionnye bolezn (2020) (published paper)
Funding: Private (Promomed, LLC)
Conflict of interest: No
Multicenter / Russia |
Follow-up duration (days): 30
Initial dose: 1600 mg orally twice on the first day. Maintenance dose: 600 mg orally twice a day for the next 13 days.
|Characteristics of participants|
Mean age : NR
Severity : Mild: n=0 / Moderate: n=200 / Severe: n=0 Critical: n=0
Number of vaccinated participants: NR
|In the register|
Rate of Clinical Status Improvement [ Time Frame: By Visit 3, approximately 10 days ] and Time to Clinical Improvement [ Time Frame: 28 days ]
|In the report|
Time to clinical improvement – a decrease by 1 category in the assessment on the Categorical scale of clinical improvement of the World Health Organization…, and the number pf patients who achieved improvement by 2 categories
Yes. In English
Data-sharing willing stated in the publication:
|Risk of bias
The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review
The published article (in Russian), trial registry (with results), study protocol and statistical analysis plan were used in data extraction and assessment of risk of bias. The target sample size specified in the registry was achieved. There is no change from the trial registration in the outcomes or intervention and control treatments.
This study was updated on February 1st, 2021 after contact with authors.